Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30763448 | 1.00 | HRH4 (0.71) | HRH4HTR3A | |
| SCHEMBL21686896 | 0.88 | HRH4 (0.79) | HRH4HTR3A | |
| SCHEMBL30763352 | 0.88 | HRH4 (0.79) | HRH4HTR3A | |
| SCHEMBL23874424 | 0.88 | HRH4 (0.66) | HRH4HTR3A | |
| SCHEMBL21686822 | 0.87 | HRH4 (0.53) | HRH4 | |
| SCHEMBL23855484 | 0.85 | HRH4 (0.72) | HRH4HTR3A | |
| SCHEMBL3758218 | 0.83 | HRH4 (1.00) | HRH4HTR3A | |
| SCHEMBL3766640 | 0.83 | HRH4 (1.00) | HRH4HTR3A | |
| SCHEMBL3762163 | 0.83 | HRH4 (1.00) | HRH4HTR3A | |
| SCHEMBL21633724 | 0.81 | HRH4 (0.73) | HRH4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492199-B2 | Pyridopyrimidines as histamine H4-receptor inhibitors | FAES FARMA, S.A. (ES) | 2025-12-09 | — | — | US | disclosed |
| EP-3827005-B1 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS | FAES FARMA SA (ES) | 2022-08-17 | — | — | EP | disclosed |
| US-20210300922-A1 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS | FAES FARMA, S.A. (ES) | 2021-09-30 | — | — | US | disclosed |
| US-20210300922-A1 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS | FAES FARMA, S.A. (ES) | 2021-09-30 | — | — | US | disclosed |
| EP-3827005-A1 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS | FAES FARMA, S.A. (ES) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020020939-A1 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS | FAES FARMA, S.A. (ES) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020020939-A1 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS | FAES FARMA, S.A. (ES) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300922-A1 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3A 95/4885 |
| US-12492199-B2 | Pyridopyrimidines as histamine H4-receptor inhibitors | HRH4, HRH2, HRH3 | HRH4 1/4885HTR3A 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.